Gibraltar Capital Management Has Lifted Rockwell Collins (COL) Position by $2.20 Million; Share Price Rose; Blue Fin Capital Has Cut Its Johnson & Johnson Com (JNJ) Holding as Stock Rose

December 7, 2017 - By Adrian Mccoy

Blue Fin Capital Inc decreased its stake in Johnson & Johnson Com (JNJ) by 12.19% based on its latest 2017Q2 regulatory filing with the SEC. Blue Fin Capital Inc sold 2,685 shares as the company’s stock rose 6.85% with the market. The institutional investor held 19,345 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $2.56 million, down from 22,030 at the end of the previous reported quarter. Blue Fin Capital Inc who had been investing in Johnson & Johnson Com for a number of months, seems to be less bullish one the $376.44B market cap company. The stock decreased 0.67% or $0.94 during the last trading session, reaching $140.12. About 408,952 shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 7, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Gibraltar Capital Management Inc increased its stake in Rockwell Collins Inc (COL) by 68.95% based on its latest 2017Q2 regulatory filing with the SEC. Gibraltar Capital Management Inc bought 20,938 shares as the company’s stock rose 9.83% with the market. The institutional investor held 51,304 shares of the capital goods company at the end of 2017Q2, valued at $5.39M, up from 30,366 at the end of the previous reported quarter. Gibraltar Capital Management Inc who had been investing in Rockwell Collins Inc for a number of months, seems to be bullish on the $21.84 billion market cap company. The stock increased 0.17% or $0.22 during the last trading session, reaching $133.45. About 46,464 shares traded. Rockwell Collins, Inc. (NYSE:COL) has risen 16.15% since December 7, 2016 and is uptrending. It has underperformed by 0.55% the S&P500.




Investors sentiment increased to 2.72 in Q2 2017. Its up 1.41, from 1.31 in 2017Q1. It increased, as 39 investors sold COL shares while 97 reduced holdings. 123 funds opened positions while 247 raised stakes. 122.00 million shares or 17.73% more from 103.63 million shares in 2017Q1 were reported. Castleark Mngmt holds 0.01% or 4,310 shares in its portfolio. Secor Advsr Lp reported 49,503 shares. Ohio-based Strs Ohio has invested 0.06% in Rockwell Collins, Inc. (NYSE:COL). Hsbc Public Ltd Company has 404,599 shares for 0.08% of their portfolio. Nj State Employees Deferred Compensation Plan accumulated 8,000 shares or 0.16% of the stock. Alabama-based Birmingham Cap Mngmt Al has invested 0.13% in Rockwell Collins, Inc. (NYSE:COL). Macquarie Grp Ltd accumulated 0.03% or 173,575 shares. Jane Street Grp Incorporated Limited Co has invested 0% in Rockwell Collins, Inc. (NYSE:COL). Westpac holds 0% or 9,829 shares in its portfolio. M Secs has invested 0.13% in Rockwell Collins, Inc. (NYSE:COL). Mountain Pacific Invest Advisers Id accumulated 211,253 shares. Fmr Lc has 4.24M shares for 0.06% of their portfolio. New England Rech Mgmt holds 0.47% or 6,025 shares. State Common Retirement Fund holds 0.08% or 595,481 shares. Cipher Cap Lp owns 48,409 shares.

More recent Rockwell Collins, Inc. (NYSE:COL) news were published by: Nasdaq.com which released: “Rockwell Collins Inc (COL) Files 10-K for the Fiscal Year Ended on September …” on November 14, 2017. Also Fool.com published the news titled: “What to Expect From United Technologies in 2018” on December 04, 2017. Nasdaq.com‘s news article titled: “Rockwell Collins, Inc. (COL) Ex-Dividend Date Scheduled for November 10, 2017” with publication date: November 09, 2017 was also an interesting one.

Among 22 analysts covering Rockwell Collins (NYSE:COL), 5 have Buy rating, 1 Sell and 16 Hold. Therefore 23% are positive. Rockwell Collins had 69 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Rockwell Collins, Inc. (NYSE:COL) has “Hold” rating given on Wednesday, September 6 by Drexel Hamilton. The rating was maintained by Cowen & Co with “Hold” on Thursday, August 3. The company was maintained on Thursday, September 7 by RBC Capital Markets. The firm earned “Market Perform” rating on Monday, September 11 by Bernstein. The rating was initiated by Robert W. Baird on Thursday, October 6 with “Neutral”. RBC Capital Markets maintained Rockwell Collins, Inc. (NYSE:COL) rating on Friday, November 10. RBC Capital Markets has “Hold” rating and $140.0 target. The company was maintained on Wednesday, April 26 by Goldman Sachs. The stock of Rockwell Collins, Inc. (NYSE:COL) has “Buy” rating given on Wednesday, July 29 by Argus Research. The stock of Rockwell Collins, Inc. (NYSE:COL) earned “Overweight” rating by Morgan Stanley on Monday, March 13. The stock of Rockwell Collins, Inc. (NYSE:COL) has “Hold” rating given on Tuesday, September 5 by Deutsche Bank.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 13 have Buy rating, 5 Sell and 5 Hold. Therefore 57% are positive. Johnson & Johnson had 83 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by UBS given on Tuesday, September 22. The rating was maintained by RBC Capital Markets on Wednesday, July 20 with “Outperform”. The firm has “Outperform” rating given on Tuesday, August 25 by Cowen & Co. As per Wednesday, April 20, the company rating was maintained by Goldman Sachs. Argus Research maintained the stock with “Buy” rating in Wednesday, October 18 report. The rating was maintained by Jefferies with “Buy” on Wednesday, October 18. BMO Capital Markets maintained it with “Buy” rating and $152.0 target in Tuesday, October 17 report. As per Friday, June 16, the company rating was maintained by Jefferies. On Monday, March 14 the stock rating was upgraded by Goldman Sachs to “Neutral”. As per Friday, July 21, the company rating was downgraded by Atlantic Securities.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: “Better Buy: Pfizer Inc. vs. Johnson & Johnson” on December 01, 2017, also Fiercebiotech.com with their article: “Johnson & Johnson’s JLABS looks east as it lands in Shanghai” published on December 05, 2017, Seekingalpha.com published: “The Right Time To Buy Johnson & Johnson” on November 17, 2017. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson: Buy The Pause” published on November 29, 2017 as well as Fool.com‘s news article titled: “Will 2018 Be Johnson & Johnson’s Best Year Yet?” with publication date: December 04, 2017.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 EPS, up 8.86% or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62B for 20.37 P/E if the $1.72 EPS becomes a reality. After $1.90 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.